Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data
Tang et al., International Journal of Clinical Pharmacy, doi:10.1007/s11096-021-01311-5
Tang et al., Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality.., International Journal of Clinical Pharmacy, doi:10.1007/s11096-021-01311-5
Jul 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Disproportionality analysis showing higher risk of liver injury with lopinavir/ritonavir for COVID-19 patients. Paxlovid combines nirmatrelvir and ritonavir.
Tang et al., 30 Jul 2021, peer-reviewed, 8 authors.
Contact: tang.huilin@ufl.edu.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Abstract: International Journal of Clinical Pharmacy (2021) 43:1116–1122 https://doi.org/10.1007/s11096-021-01311-5 RESEARCH ARTICLE Drug‑induced liver injury associated with lopinavir‑ritonavir in patients with COVID‑19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data Huilin Tang1 · Liyuan Zhou2 · Xiaotong Li3 · Alan C. Kinlaw4,5 · Jeff Y. Yang6 · Andrew M. Moon7,8 · Edward L. Barnes7,8 · Tiansheng Wang6 Received: 4 May 2021 / Accepted: 21 July 2021 / Published online: 30 July 2021 © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 Abstract Background Liver injury has been documented independently in novel coronavirus disease 2019 (COVID-19) patients and patients treated with lopinavir-ritonavir. Objective to investigate the drug-induced liver injury associated with lopinavirritonavir among the patients with COVID-19. Methods We conducted a disproportionality analysis of US Food and Drug Administration Adverse Event Reporting System (FAERS) between 2020Q1 and 2021Q1 to evaluate the association between lopinavir-ritonavir and risk of drug-induced liver injury (or severe drug-induced liver injury) and calculated their reporting odds ratios (RORs) with 95% confidence intervals (CIs). Results A total of 3,425 cases of drug-induced liver injury were reported in 19,782 patients with COVID-19. The ROR for drug-induced liver injury was 2.99 (2.59–3.46), 3.16 (2.68–3.73), and 5.39 (4.63–6.26) when comparing lopinavir-ritonavir with all other drugs, hydroxychloroquine/chloroquine only, and remdesivir, respectively. For severe drug-induced liver injury, RORs for lopinavir-ritonavir provided evidence of an association compared with all other drugs (3.98; 3.15–5.05), compared with hydroxychloroquine/chloroquine only (5.33; 4.09–6.94), and compared with remdesivir (3.85; 3.03–4.89). Conclusions In the FAERS, we observed a disproportional signal for druginduced liver injury associated with lopinavir-ritonavir in patients with COVID-19. Keywords FAERS · Liver injury · Lopinavir-ritonavir · Novel coronavirus disease 2019 Impacts on practice • COVID-19 patients treated with lopinavir-ritonavir are at increased risk of liver injury. Huilin Tang and Liyuan Zhou contributed equally to this work * Huilin Tang tang.huilin@ufl.edu 1 Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, FL, USA 2 Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA 3 Institute for Drug Evaluation, Peking University Health Science Center, Beijing, China 4 Division of Pharmaceutical Outcome and Policy, University of North Carolina School of Pharmacy, Chapel Hill, NC, USA 13 Vol:.(1234567890) 5 Cecil G. Sheps Center for Health Services Research, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA 6 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA 7 Center for Gastrointestinal Biology and Disease, School of Medicine, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA 8 Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina At Chapel Hill, Chapel Hill, NC, USA International Journal of Clinical Pharmacy (2021) 43:1116–1122 • The risk of liver injury reinforces recent..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit